Login to Your Account



‘It’s a Revolution!’

Oral Therapies Seize the Spotlight in MS

By Marie Powers
Staff Writer

Monday, November 4, 2013

Stellar third quarter earnings reported last week by Biogen Idec Inc., including another home run for the company with Tecfidera (dimethyl fumarate), put a spotlight on the promising pipeline of next-generation multiple sclerosis (MS) drugs. Weston, Mass.-based Biogen is smack in the middle of that hunt. In addition to its four commercial MS products – Ampyra/Fampyra (dalfampridine), Avonex (interferon beta-1a), Tysabri (natalizumab) and Tecfidera – the company has two MS drugs in Phase III development: Plegridy (peginterferon beta-1a) and anti-IL2 antibody daclizumab, which is partnered with Abbvie Inc., of Chicago.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription